Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 20/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | APLNR | P35414 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | CX3CR1 | P49238 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimavanserin SCHEMBL675165 | 1.00 | HTR2A (1.00) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| SCHEMBL20794857 | 0.96 | HTR2A (0.93) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL971246 | 0.96 | HTR2A (0.93) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| SCHEMBL20766842 | 0.96 | HTR2A (0.93) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL971607 | 0.96 | HTR2A (0.93) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Succinic Acid SCHEMBL28763260 | 0.96 | HTR2A (0.91) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL970683 | 0.96 | HTR2A (0.91) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL1395694 | 0.95 | HTR2A (0.90) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL969828 | 0.95 | HTR2A (0.90) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL969826 | 0.95 | HTR2A (0.90) | HTR2AHTR2CABCB11CYP1A2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020020064-A1 | METHOD FOR SAFELY PREPARING PIMAVANSERIN AND TARTRATE SALT THEREOF USING TRIPHOSGENE | 丽珠集团新北江制药股份有限公司 | 2020-01-30 | — | — | WO | claimed |
| CN-102153505-B | n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation and crystalline form of its tartrate | ACADIA PHARMACEUTICAL, INC. (US) | 2014-10-22 | — | — | CN | claimed |
| CN-101035759-A | Synthesis and crystalline forms of N- (4-fluorobenzyl) -N- (1-methylpiperidin-4-yl) -N' - (4- (2-methylpropyloxy) phenylmethyl) urea and its tartrate salt | ACADIA PHARM INC (US) | 2007-09-12 | — | — | CN | claimed |
| CN-101031548-A | Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy) phenylmethyl) carbamide and their preparation | ACADIA PHARM INC (US) | 2007-09-05 | — | — | CN | claimed |
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | ACADIA PHARMACEUTICALS INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20220024871-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | ACADIA PHARMACEUTICALS INC. | 2022-01-27 | — | — | US | disclosed |
| WO-2020020064-A1 | METHOD FOR SAFELY PREPARING PIMAVANSERIN AND TARTRATE SALT THEREOF USING TRIPHOSGENE | 丽珠集团新北江制药股份有限公司 | 2020-01-30 | — | — | WO | disclosed |
| CN-102153505-B | n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation and crystalline form of its tartrate | ACADIA PHARMACEUTICAL, INC. (US) | 2014-10-22 | — | — | CN | disclosed |
| WO-2014085362-A1 | METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS USING PIMAVANSERIN | ACADIA PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| CN-102153505-A | Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation | ACADIA PHARM INC | 2011-08-17 | — | — | CN | disclosed |
| CN-101035759-B | Synthesis and crystalline forms of N- (4-fluorobenzyl) -N- (1-methylpiperidin-4-yl) -N' - (4- (2-methylpropyloxy) phenylmethyl) urea and its tartrate salt | ACADIA PHARM INC | 2011-06-15 | — | — | CN | disclosed |
| CN-101031548-B | Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy) phenylmethyl) carbamide and their preparation | ACADIA PHARM INC | 2011-04-06 | — | — | CN | disclosed |
| CN-101035759-A | Synthesis and crystalline forms of N- (4-fluorobenzyl) -N- (1-methylpiperidin-4-yl) -N' - (4- (2-methylpropyloxy) phenylmethyl) urea and its tartrate salt | ACADIA PHARM INC (US) | 2007-09-12 | — | — | CN | disclosed |
| CN-101031548-A | Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy) phenylmethyl) carbamide and their preparation | ACADIA PHARM INC (US) | 2007-09-05 | — | — | CN | disclosed |
| EP-1794126-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | Acadia Pharmaceuticals Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006037043-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. (US) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | NR3C2, NR2C2, CYP4A22 | HTR2A 911/4885HTR2C 838/4885ABCB11 2727/4885 |
| US-20220024871-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | NR3C2, NR2C2, CYP4A22 | HTR2A 919/4885HTR2C 846/4885ABCB11 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.